Proactiveinvestors RSS feed en Thu, 30 Mar 2017 21:34:04 +0100 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[RNS press release - Notice of Preliminary Results ]]> Mon, 27 Mar 2017 07:00:00 +0100 <![CDATA[Media files - NetScientific boss proud of cancer diagnostic tool's achievements ]]> Thu, 23 Feb 2017 07:49:00 +0000 <![CDATA[News - NetScientific hails commercial launch of breakthrough cancer detection device ]]> Wed, 22 Feb 2017 07:21:00 +0000 <![CDATA[RNS press release - Vortex Biosciences Launches VTX-1 Liquid Biopsy ]]> Wed, 22 Feb 2017 07:00:00 +0000 <![CDATA[News - NetScientific hails award-winning scientist ]]> NetScientific PLC (LON:NSCI), the healthcare investment group, said the chief scientific officer of one of its investee companies has won industry recognition.

Vortex Biosciences' Elodie Sollier-Christen received the 2017 Society award for Laboratory Automation and Screening Innovation.

Her presentation to the judges was entitled Vortex Technology for fast and label-free isolation of circulating tumour cells from blood samples.

In it she discussed a breakthrough by Vortex in the isolation of circulating tumour cells from blood samples.

NetScientific chief executive François Martelet said: "We wish to extend our warm congratulations to Elodie on her receipt of this prestigious award.

“We view this prize as a recognition of her extraordinary work on the cutting edge technology utilised by  Vortex on the design of the VTX-1 liquid biopsy system.

“We believe that this technology has great potential to significantly impact laboratory automation and screening and we are delighted to see it receive due recognition."

Wed, 15 Feb 2017 07:54:00 +0000
<![CDATA[RNS press release - Vortex Biosciences CSO Wins SLAS Innovation Award ]]> Wed, 15 Feb 2017 07:00:00 +0000 <![CDATA[RNS press release - Vortex Biosciences CSO Finalist for SLAS Award ]]> Thu, 09 Feb 2017 07:00:00 +0000 <![CDATA[RNS press release - Grant of Options to Directors ]]> Mon, 30 Jan 2017 07:00:00 +0000 <![CDATA[News - NetScientific announces new CEO for portfolio company Wanda ]]> NetScientific PLC (LON:NSCI), the backer of fledgling healthcare companies, said digital health company Wanda has a new chief executive officer.

Foad Dabiri, who has been Wanda’s chief technology officer since March 2014, will be taking over from Steve Curd as chief executive officer (CEO) with immediate effect.

Curd had been Wanda’s CEO since September 2015.

Dabiri will take the company through its commercialisation stage, said NetScientific.

"Foad's unique understanding of the nexus between predictive analytics, data and patient need, make him the best person to lead Wanda at this critical juncture as it moves into its commercialisation phase,” said François Martelet, who is CEO of NetScientific and chairman of Wanda.

San Francisco-based Wanda is one of NetScientific’s portfolio companies.

It is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions.

Tue, 20 Dec 2016 07:42:00 +0000
<![CDATA[RNS press release - New CEO appointed to Wanda ]]> Tue, 20 Dec 2016 07:00:00 +0000 <![CDATA[News - NetScientific provides more backing for cancer immunotherapies developer ]]> NetScientific PLC (LON:NSCI) has upped its stake in PDS Biotechnology, a developer of cancer immunotherapies and vaccines for infectious diseases.

The Aim-listed firm exercised warrants for 1.39mln shares at a cost of US$687,493.

NetScientific has now invested a total of US$3.5ln in PDS Biotechnology, giving it a 14.6% stake.

PDS is operating in the exciting area of immuno-oncology – activating the body's own immune system to recognise and destroy cancer cells.

The field has caused a lot of excitement in the medical world, but one of the major drawbacks has been reports of debilitating toxicities – a drawback PDS has conquered with its Versamune T-cell (a type of white blood cell) activating platform.

PDS's cancer treatment pipeline includes compounds for prostate, ovarian, breast and colorectal cancers, in addition to its lead PDS0101 programme for several HPV-related cancers – HPV, or human papillomavirus, being a virus that infects the skin and the cells lining body cavities.

PDS has positive phase I/IIa trial data under its belt and has agreed partnership funding from the National Institute of Health and MD Anderson for three phase II clinical trials.

Shares in NetScientific rose 2.3% to 67p on the news.

Fri, 16 Dec 2016 08:18:00 +0000
<![CDATA[RNS press release - Executed Warrants ]]> Fri, 16 Dec 2016 07:00:00 +0000 <![CDATA[RNS press release - Netscientific: Vortex Biosciences Analysis Data ]]> Fri, 18 Nov 2016 07:00:00 +0000 <![CDATA[Media files - NetScientific plc chief hails progress at Vortex Biosciences ]]> Mon, 07 Nov 2016 09:15:00 +0000 <![CDATA[News - NetScientific shares gain as Vortex makes commercialisation progress ]]> NetScientific plc (LON:NSCI) shares nudged higher as it revealed portfolio company Vortex Biosciences had moved closer to selling its circulating tumour cell (CTC) capture system in the USA and Europe.

Vortex has registered a Class I medical device with the US FDA (Food and Drug Administration) and established a CE Mark for the proprietary technology.

NetScientific's chief executive and chairman of Vortex, Francois Martelet, said: "Both the CE Mark and FDA Class 1 registration are significant milestones achieved towards making VTX-1 commercially available in early 2017 and bringing us closer to the sale of the system in the clinical market in the US."

The CE Mark allows Vortex to install systems in the European Economic Area (EEA).

It will initially be distributed for research use only. The FDA Class 1 registration is a first step towards the sale of the system in the clinical market

The Vortex VTX-1 liquid biopsy system is a fully automated benchtop system for collecting intact CTCs.

CTCs, shed by cancer tumors, can potentially allow for better characterisation of the disease, resulting in better treatment decisions.

Cancer cells are traditionally obtained through tissue biopsies but these are costly, painful, often not possible.

Shares added 6.3% to stand at 67.5p.

Fri, 04 Nov 2016 08:43:00 +0000
<![CDATA[RNS press release - Vortex Gains CE Mark and FDA Class 1 Registration ]]> Thu, 03 Nov 2016 16:34:00 +0000 <![CDATA[News - Vortex Bio gains FDA registration for Class 1 medical device ]]> Vortex Biosciences, a provider of circulating tumor cell (CTC) capture systems, Thursday announced it has registered a Class I medical device with the US Food and Drug Administration and established a CE Mark for its proprietary CTC capture system, the VTX-1 Liquid Biopsy System.

Vortex is a portfolio company of the UK’s NetScientific plc (AIM:NSCI, LON:NSCI), the transatlantic healthcare IP commercialisation group.

"Both the CE Mark and FDA Class 1 registration are significant milestones achieved towards making VTX-1 commercially available in early 2017 and bringing us closer to the sale of the system in the clinical market in the US," said Chief Executive Officer and Chairman of Vortex, Francois R. Martelet.

The CE Mark allows Vortex to install systems in the European Economic Area (EEA). VTX-1 will initially be distributed into the Research Use Only (RUO) market. The FDA Class 1 registration is a first step towards the sale of the system in the clinical market.

A CE mark indicates the VTX-1 has met all applicable directives of the European Commission (EC) and subsequently the laws and regulations of the European Union (EU) member states and therefore can be commercialized within the 30-nation EEA and Switzerland. The establishment of this CE mark involved thorough evaluation and testing of the VTX-1 to assure it performs safely and as designed.  The FDA Class 1 registration ensures we are operating within FDA guidelines for the use of the system.

Representative of cancer status in the patient, CTCs, shed by tumors, can potentially allow for better characterisation of the disease, resulting in more informed treatment decisions. Cancer cells are traditionally obtained through tissue biopsies. Biopsies are costly, painful, often not possible, and cannot be performed on all possible tumor sites.

CTCs offer tremendous potential, but are relatively scarce, with concentrations as low as 1-10 CTCs/mL of whole blood, against a background of millions of white blood cells and billions of red blood cells. Capturing CTCs out of whole blood is a critical step in utilising CTCs for cancer diagnosis, better cancer treatment decisions and disease monitoring.

The Vortex VTX-1 Liquid Biopsy System is a fully automated benchtop system for collecting intact CTCs using microfluidic technology. Inside the VTX-1 chip, unlabeled CTCs in whole blood are trapped in microscale vortices while smaller red and white blood cells pass through. After selective trapping into the microfluidic chambers, CTCs can be flushed and collected into a variety of containers for downstream analysis.

The Vortex CTC isolation process is label-free and contact-free, keeping CTCs intact and viable. Samples processed by the VTX-1 minimize white blood cell contamination, resulting in a highly pure CTC sample with minimal white blood cell contamination.

Thu, 03 Nov 2016 16:05:00 +0000
<![CDATA[News - NetScientific's Vortex Biosciences has new director ]]> NetScientific PLC (LON:NSCI) said portfolio firm and circulating tumor cell group  Vortex Biosciences has hired Deborah Neff as a non-executive director.

She will play a critical role providing strategic oversight, as its circulating tumor cell enrichment system, the VTX-1, is progressed towards commercialisation, Netscientific said.

Neff has served in a number of leadership positions in healthcare companies, including a 15-year career at Becton Dickinson & Co in executive management positions,

The planned commercial launch of the VTX-1 system is planned for the first quarter of 2017.

It is a fully automated benchtop system for capturing intact circulating tumor cells (CTCs) directly from whole blood samples without any preprocessing steps.

CTCs, shed by cancer tumors, can potentially reveal disease recurrence or disease progression earlier than imaging and more reliably compared with standard biomarkers.

Wed, 26 Oct 2016 14:59:00 +0100
<![CDATA[RNS press release - Vortex Biosciences Appoints Non-Executive Director ]]> Wed, 26 Oct 2016 12:30:00 +0100 <![CDATA[Media files - NetScientific’s ProAxsis sees big European market open up; next stop: USA ]]> Fri, 30 Sep 2016 14:48:00 +0100 <![CDATA[News - NetScientific celebrates CE mark breakthrough for its ProAxsis unit ]]> NetScientific PLC (LON:NSCI) said ProAxsis, its medical diagnostics company, has successfully registered a CE Mark for its novel ProteaseTag Active Neutrophil Elastase Immunoassay.

The healthcare intellectual property commercialisation group said the breakthrough will enable its Northern Ireland-based portfolio company to proceed to the commercialisation stage of its biochemical test in the European Union.

“We are delighted that ProAxsis has achieved a significant milestone in successfully CE marking its novel ProteaseTag Active Neutrophil Elastase Immunoassay for chronic respiratory diseases. This will help accelerate its commercialisation in the COPD and Cystic Fibrosis markets,” said François Martelet, chairman of ProAxsis and chief executive officer of NetScientific.

"ProAxsis is now able to sell its immunoassay in the 28 member states of the European Union, as well as Switzerland, Turkey, Iceland, Norway and Liechtenstein. Achieving CE Mark for its immunoassay demonstrates the company's clear commitment to delivering first-class quality products to physicians and their patients who suffer from chronic respiratory diseases," Martelet said.

Dr David Ribeiro, chief executive officer of ProAxsis, said the company had already had enquiries from a number of pharmaceutical companies concerning the commercial use of the immunoassay in their upcoming clinical trials.

Fri, 30 Sep 2016 07:34:00 +0100
<![CDATA[RNS press release - ProAxsis Gains CE Mark for its Respiratory Test ]]> Fri, 30 Sep 2016 07:00:00 +0100 <![CDATA[Media files - NetScientific PLC focused on “execution, execution and execution” ]]> Tue, 27 Sep 2016 15:35:00 +0100 <![CDATA[News - NetScientific revitalised by focus on core portfolio ]]> Pre-revenue healthcare intellectual property (IP) commercialisation group NetScientific PLC (LON:NSCI) said its core portfolio companies made excellent progress in the first half of 2016.

The big four players in NetScientific’s roster are: Wanda, Vortex Biosciences, Glycotest and ProAxsis.


Wanda is a San Francisco-based digital health company focused on reducing hospitalisation risk and improving the quality of life for those suffering chronic conditions.

It has developed a way to digitally monitor people with congestive heart failure and other chronic conditions, so that specialists can monitor risk and lower readmissions. The latter is significant because in the US the system means hospitals have to pay when patents are discharged then re-admitted.

During the reporting period it signed a contract with a leading US high-tech home nursing and therapy services agency, Health Resource Solutions (HRS), for the use of its chronic condition management product. HRS looks after more than 1,000 patients per month helping them to have a higher quality of life at home rather than in hospitals. The agreement is demonstrating early signs of commercial success, NetScientific said.

In addition, Wanda signed a collaborative agreement with the fifth largest health provider organisation in the US, Dignity Health, to launch its new oncology platform, Oncoverse. The platform allows clinicians to work together to establish the most effective treatment plan and helps to reduce administration costs.

Post-reporting period Wanda has broadened its commercialisation strategy to include a direct-to-consumer offering with the launch of myWanda, the only mobile application specifically aimed at empowering women to improve the health of their hearts.

The group said the app is already attracting interest from large employers.

Vortex Biosciences

Vortex Biosciences is a US based cancer diagnostic company, developing a novel liquid biopsy automated instrument, VTX-1, and microfluidic cartridge for the isolation of circulating tumour cells from whole blood without the need for any pre-processing of the blood.

In the first half of 2016, the VTX-1 instrument and the integrated microfluidic cartridge moved from feasibility into late stage development. The aim is for a commercial launch into the clinical research market in the first quarter of next year.


Glycotest is a US-based liver diagnostics company seeking to commercialise new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis with exclusive worldwide rights to more than 50 patent-protected serum protein biomarkers.

A clinical study of its lead product, HCC Panel, demonstrated the product’s ability to detect early-stage liver cancer significantly better than the alpha-fetoprotein blood test, which is the current standard in healthcare.


ProAxsis is a Northern Ireland-based medical diagnostics company, developing a range of laboratory assays and point-of-care tests designed for the capture, detection and measurement of active protease biomarkers of diseases.

NetScientific said ProAxsis continued to make excellent progress in the first half of the year with its ProteaseTag Active Neutrophil Elatase Immunoassay, which was increasingly being used by academic research centres and pharmaceutical companies focused on respiration issues.

Management comment

"NetScientific has undergone a transformation under the leadership of François Martelet, with the rationalisation of the portfolio and restructuring of the management team, resulting in a streamlined group focused on IP commercialisation,” said Sir Richard Sykes, executive chairman of NetScientific, adding that the portfolio focus has been totally revitalised.

Chief executive Martelet said: "During the period I am delighted to say that four of our core portfolio companies made significant operational and development progress, positioning themselves optimally to initiate external financing rounds with the goal of providing significant value inflection points upon completion."

The group has ambitions to strengthen its transatlantic focus through organic and strategic growth, actively managing the portfolio and replenishing the pipeline with disruptive chronic disease opportunities, it said.

Delivering near-term milestones remains a focus with key deliverables including: completing external financing for Wanda/Glycotest, a product launch for Vortex and ProAxsis achieving a CE mark for its NEATstik point-of-care device.

Numbers are not particularly meaningful for a company at this stage of development, but for the record revenue in the first half of 2016 grew to £359,243 from £55,000 the year before, while the loss before tax widened to £6.13mln from £4.39mln.

Available cash at the end of June had diminished to £15.9mln from £23.2mln at the end of 2015.


Tue, 27 Sep 2016 14:42:00 +0100
<![CDATA[RNS press release - NetScientific Interim Results ]]> Tue, 27 Sep 2016 07:00:00 +0100 <![CDATA[News - NetScientific’s Wanda chosen by 24Hr HomeCare ]]> Netscientific PLC’s (LON:NSCI) portfolio company Wanda will supply its home-centred care technology to LA-based care services firm 24Hr HomeCare.

24Hr HomeCare will use Wanda’s predicative analytics and behavioural guidance technology to improve outcomes for at-risk patients and reduce hospital readmissions.

"24Hr HomeCare's decision to use Wanda's home-centred care technology…is an excellent endorsement of Wanda's growing reputation as a digital healthcare technology,” said NetScientific chief executive François Martelet.

LA-based 24Hr HomeCare said it will deploy the technology immediately, adding that it would be “a huge asset” by allowing the company to monitor patients between visits.

There were other options on the table, 24Hr HomeCare said, but Wanda’s offering “stood out”.

As well as allowing for the remote monitoring of patients, Wanda’s technology can predict a patient’s future health, by providing an “advanced look into the patient’s most likely future”.

Shares in NetScientific were up 12% to 84.5p. 

Fri, 23 Sep 2016 10:34:00 +0100
<![CDATA[RNS press release - Wanda Technology Selected by 24Hr HomeCare ]]> Fri, 23 Sep 2016 07:00:00 +0100 <![CDATA[News - NetScientific's Glycotest granted Japanese patent for liver disease test ]]> NetScientific plc's (LON:NSCI) portfolio company Glycotest, has been granted a Japanese patent for its core technology for the early detection of life threatening liver disease.

The patent joins five others previously granted across Australia, US and Japan, covering the use of over 50 unique glycoprotein biomarkers for the diagnosis of liver cancers and diseases.

The group said it soon expects to announce positive developments in the patent protection of the proprietary assay technology required to measure these novel biomarkers.

Glycotest is a private liver disease diagnostics platform commercialising novel clinical laboratory testing services to detect liver cancers and diseases, such as fibrosis-cirrhosis.

Chief executive Lawrence Cohen said the group's intellectual property portfolio along with outstanding clinical results achieved to date had potential to form the base of what it expected to be a very strong company in liver disease diagnostics.

"The Glycotest patent portfolio is becoming substantial and we expect more good news in the coming year regarding our intellectual property position," he said.

Mon, 12 Sep 2016 08:13:00 +0100
<![CDATA[RNS press release - Glycotest strengthens IP portfolio ]]> Mon, 12 Sep 2016 07:00:00 +0100 <![CDATA[News - NetScientific’s Wanda appoints new non-exec ]]> Netscientific PLC’s (LON:NSCI) digital health portfolio company Wanda has told investors that it has appointed Derek Newell to its board as a non-executive director.

Newell is currently the chief executive of enterprise health benefits platform, Jiff, and Wanda has brought him on board to take advantage of his extensive experience in the healthcare sector.

On top of his role at Jiff, he was previously the president and chief executive at Robert Bosch Healthcare, chief executive at Health Hero Networks and has also worked for LifeMasters.

"Derek is a highly regarded and knowledgeable industry leader with vast experience in the field of innovative health technology,” said NetScientific chief executive and Wanda chairman François Martelet.

“We are delighted that Wanda has further strengthened its Board with a digital health expert of his calibre."

Wanda chief executive Steve Curd echoed those thoughts, explaining: “I am confident that Derek will offer tremendous insights and provide us with a unique perspective as we continue to advance our technical, operational, and financial objectives."

Shares in NetScientific were down 2%, or 1.5p, to 72p.

Thu, 08 Sep 2016 08:16:00 +0100
<![CDATA[RNS press release - Wanda Appoints Digital Health Non-Exec Director ]]> Thu, 08 Sep 2016 07:00:00 +0100 <![CDATA[RNS press release - Notice of Interim Results ]]> Tue, 06 Sep 2016 07:00:00 +0100 <![CDATA[Media files - Netscientific PLC chief executive very excited about heart health phone app ]]> Fri, 19 Aug 2016 13:37:00 +0100 <![CDATA[News - App-y days as NetScientific’s portfolio company Wanda launches phone app ]]> Netscientific PLC's (LON:NSCI) digital health portfolio company Wanda has launched a phone app today aimed at helping women improve the health of their hearts.

MyWanda, the first app of its kind, will offer personalised daily tips, advice and inspiration to encourage women to develop “heart healthy behaviours”.

“We’re excited to bring a technology solution to market that can truly inform, motivate and support women to take better care of their hearts,” said Wanda chief executive Steve Curd.

NetScientific’s chief executive François Martelet added: “This is an important milestone for Wanda and is in line with the company’s strategy to expand its platform of mobile applications to capture patients earlier in their disease trajectory.”

Heart disease is the number one killer of women in America, although San Francisco-based Wanda estimates that around 80% of cases are preventable through education and lifestyle changes.

The company has called the new app, which is available on the US iTunes App Store, a “revolution in healthcare”.

As well as helping women to take control of their health, the app will add to Wanda’s current data and understanding of women’s heart health.

Shares in NetScientific were down 1p, or 1.3%, to 76p.

Fri, 19 Aug 2016 07:41:00 +0100
<![CDATA[RNS press release - Wanda Launches First Consumer App ]]> Fri, 19 Aug 2016 07:00:00 +0100 <![CDATA[News - NetScientific appoints new scientific advisory board ]]> Healthcare technology group NetScientific plc (LON:NSCI) has made a number of appointments to its newly formed scientific advisory board (SAB) at its portfolio company Vortex Biosciences.

The board comprises of distinguished clinicians and bioengineers in the field of oncology and circulating tumour cells (CTC).

It will provide strategic guidance in decision-making to support the development and commercialization of Vortex's CTC enrichment system for both the research and diagnostic markets.

"We are thrilled to have attracted some of the world's leading experts in circulating tumor cells, oncology, clinical trials and microfluidics to help us define our clinical strategy as we commercialize our next generation CTC enrichment system, the VTX-1," said Vortex chief executive Gene Walther.

"The formation of our SAB serves as an endorsement of the scientific and clinical enthusiasm for the Vortex technology."

Thu, 18 Aug 2016 07:58:00 +0100
<![CDATA[RNS press release - Vortex Biosciences Appoints Experts to New SAB ]]> Thu, 18 Aug 2016 07:06:00 +0100 <![CDATA[News - NetScientific investee company strikes Harvard licensing deal ]]> The AIM-listed healthcare technology incubator, NetScientific PLC (LON:NSCI), said one of its investee companies had struck a deal with Harvard University.

Vortex Biosciences has been granted a series of licences for cell electroporation technology developed by Harvard researchers that will boost its ability to analyse circulation tumour cells (CTCs).

The patents will also “significantly strengthen” Vortex’s intellectual property base, NetScientific said in an announcement Wednesday.

Chief executive Francois Martelet: “The exclusive license of these new patents from a world leading research institution will significantly increase the ability of Vortex's technology to characterize CTCs and strengthen its ability to analyse the underlying drivers of a patient's disease as the VTX-1 moves towards commercialisation."

The VTX-1 system, introduced earlier this year, offers one of the most sophisticated ways to collect and analyse CTCs, which provide the early, tell-tale signs of the onset of cancer.

Being able to identify and capture CTCs allows earlier intervention; it may also hold the key to a personalised approach to treating the killer disease, academic research has shown.

Wed, 03 Aug 2016 07:38:00 +0100
<![CDATA[RNS press release - Vortex Licenses Patents From Harvard University ]]> Wed, 03 Aug 2016 07:00:00 +0100 <![CDATA[RNS press release - Change of Adviser ]]> Thu, 28 Jul 2016 07:00:00 +0100 <![CDATA[News - Netscientific hails Wanda’s new medical director ]]> Shares in AIM- listed biomedical firm Netscientific PLC (LON:NSCI) ticked higher as it hailed the appointment of a renowned cardiologist as medical director at its California- based portfolio firm Wanda.

She is Dr Suzanne Steinbaum, a board-certified cardiologist and well-known national advocate for women's heart health, the group said.

Wanda is a digital analytics software group, whose aim is to reduce US hospital admissions.

It has developed a way to digitally monitor people with congestive heart failure and other chronic conditions, so that specialists can monitor risk and lower readmissions.

Dr Steinbaum said: "Wanda is at the forefront of a critical turning point in healthcare, in which patient engagement is essential to successful outcomes.

"I have devoted my entire career to the treatment of heart disease through early detection, education, and prevention."

She added :"While heart disease is 80 to 90% preventable, lifestyle changes are critical, and this is where Wanda comes in."

François R. Martelet, chief executive at NetScientific said: "Dr Steinbaum's extensive clinical experience and background in cardiology will make her a valuable addition to Wanda's already distinguished team."

Shares in NetScientific added 0.67% to stand at 75.5p a pop.

Wed, 27 Jul 2016 08:23:00 +0100
<![CDATA[RNS press release - Wanda Appoints Medical Director ]]> Wed, 27 Jul 2016 07:00:00 +0100 <![CDATA[RNS press release - A to Z Home Health Care selects Wanda technologies ]]> Fri, 22 Jul 2016 07:00:00 +0100 <![CDATA[RNS press release - Grant of Options to Director ]]> Mon, 27 Jun 2016 07:00:00 +0100 <![CDATA[RNS press release - Result of AGM ]]> Wed, 15 Jun 2016 14:13:00 +0100 <![CDATA[News - NetScientific ‘totally revitalised’ under Francois Martelet, says chairman Sir Richard Sykes ]]> NetScientific Plc’s (LON:NSCI) management team and portfolio focus have been totally revitalised by Francois Martelet, who took up the position of chief executive last June.

That’s the view of the company’s chairman Sir Richard Sykes ahead of the company’s Capital Markets Day at the London Stock Exchange, which happens today.

“We now have a focused portfolio of assets which are close to commercialisation and which offer the scope for significant value creation,” Sykes said in a statement.

“We look forward to highlighting the key jewels in our crown, and to explaining how they offer opportunities both to provide patient benefit and shareholder value."

Sykes and Martelet will outline to attending investors the next steps for NetScientific in maximising value from its portfolio companies. The LSE organised event will also feature representatives from the businesses that NetScientific is invested in.

In a separate statement, NetScientific announced the appointment of Dr Massimo Cristofanilli by portfolio company Vortex Biosciences to be chairman of its newly formed scientific advisory board.

"Vortex Biosciences is at a pivotal point as its circulating tumour cell enrichment system, the VTX-1, moves towards commercialisation,” Martelet said.

“The appointment of Dr. Cristofanilli, who will be joining to spearhead the creation of Vortex's world class Scientific Advisory Board, will help underpin their clinical strategy as the company moves through this transformational period."

Tue, 14 Jun 2016 08:56:00 +0100
<![CDATA[RNS press release - NetScientific hosts Capital Markets Day ]]> Tue, 14 Jun 2016 07:00:00 +0100 <![CDATA[RNS press release - Confirmed Start Date for Ian Postlethwaite as CFO ]]> Fri, 10 Jun 2016 07:30:00 +0100 <![CDATA[News - NetScientific invests in PDS Biotech ]]> Healthcare investment company NetScientific PLC (LON:NSCI) has invested a further US$500,000 in immunotherapeutic drug development company PDS Biotechnology.

The money will help fund the Phase II trials of PDS’s Versamune cancer treatment technology, following the successful Phase I trials back in April.

“The promising results from PDS’s Phase I results have provided positive validation of the Versamune T-cell activating platform technology,” said NetScientific chief executive Francois Martelet.

PDS operates within the immunotherapy field which is a hot topic in the healthcare world at the moment.

Immunotherapy involves harnessing the body’s own defence systems to help fight cancer and other infectious diseases.

Shares in NetScientific were down 1.4p, or 1.7%, to 78.6p.

Tue, 07 Jun 2016 10:39:00 +0100
<![CDATA[RNS press release - Portfolio PDS Biotechnology presents at BIO 2016 ]]> Tue, 07 Jun 2016 07:00:00 +0100